General (Details Narrative) € in Thousands, $ in Thousands |
1 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Aug. 12, 2026 |
Mar. 02, 2026 |
Sep. 08, 2025
USD ($)
shares
|
Aug. 13, 2026
shares
|
Jan. 31, 2025
USD ($)
shares
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
May 09, 2025
USD ($)
|
May 09, 2025
EUR (€)
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
| Cash | $ 45 | € 40 | |||||||
| Accumulated deficit | $ 72,956 | $ 69,728 | |||||||
| Nasdaq stock market description | The Nasdaq Stock Market indicating that the Company is in violation of Nasdaq Listing Rule 5550(a)(2), as the closing bid price of our common stock fell below the minimum $1.00 per share threshold for 30 consecutive trading days. While the Company has been granted an initial compliance period until August 31, 2026, to regain compliance—which the Company is attempting to remedy via a Board-approved 1-for-8 reverse stock split—there is no guarantee it will meet Nasdaq’s continued listing standards. If the Company is delisted and ceases to be a publicly traded company, its ability to raise operational liquidity will be severely impaired, and it may be entirely unable to raise necessary funds through public capital markets. In addition, Nasdaq adopted a new continued listing rule requiring listed companies to maintain a minimum Market Value of Listed Securities (MVLS) of at least $5,000. However, on July 29, 2026, the SEC notified Nasdaq that it had received notices of intention to petition for review of the approval order and, pursuant to Rule 431(e) of the SEC’s Rules of Practice, the effectiveness of the approval order was automatically stayed pending further review by the SEC. As a result, the ultimate implementation, timing and scope of the MVLS requirement remains uncertain. If the rule goes into effect and the Company’s MVLS drops and remains below this $5,000 threshold for 30 consecutive business days, the Company will be subject to an immediate Staff Delisting Determination with no customary cure or compliance period. | ||||||||
| Aggregate offering price | $ 4,100 | ||||||||
| Commission percentage | 3.00% | ||||||||
| Number of shares sold | shares | 344,047 | ||||||||
| Aggregate gross proceeds | $ 3,903 | ||||||||
| Subsequent Event [Member] | |||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
| Number of shares sold | shares | 92,558,000 | ||||||||
| Reverse stock split | 1-for-8 reverse stock split | ||||||||
| Share Sale and Purchase Agreement [Member] | |||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
| Percentage of share capital | 100.00% | ||||||||
| Cash payment | $ 150 | ||||||||
| Fair value of purchase price allocation | $ 338 | ||||||||
| Share Sale and Purchase Agreement [Member] | Common Stock [Member] | |||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
| Number of shares issued | shares | 241,093 | ||||||||
| Share Sale and Purchase Agreement [Member] | Common Stock [Member] | Maximum [Member] | |||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
| Warrant to purchase shares | shares | 28,000 | ||||||||